ArticleVaccines2026

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults.

Yanely Pineiro Puebla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.